Add-Back and Combined Regulation in GnRH-a Treatment of Endometriosis
Objective: The purpose of this review is to summarize drug selection for peri-menopausal symptoms caused by gonadotropin releasing-hormone agonist (GnRH-a) in the treatment of endometriosis. Mechanism: GnRH-a treatment often leads to low estrogen levels, resulting in peri-menopausal symptoms and ost...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-10-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/50/10/10.31083/j.ceog5010224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402499664969728 |
|---|---|
| author | Huimin Tang Qiucheng Jia Zhiyong Dong Yao Chen Wulin Shan Yihan Wu Miao Miao Tingwei Xing Weiwei Wei Bin Tang Hong Zheng Ruxia Shi Bairong Xia Jiming Chen |
| author_facet | Huimin Tang Qiucheng Jia Zhiyong Dong Yao Chen Wulin Shan Yihan Wu Miao Miao Tingwei Xing Weiwei Wei Bin Tang Hong Zheng Ruxia Shi Bairong Xia Jiming Chen |
| author_sort | Huimin Tang |
| collection | DOAJ |
| description | Objective: The purpose of this review is to summarize drug selection for peri-menopausal symptoms caused by gonadotropin releasing-hormone agonist (GnRH-a) in the treatment of endometriosis. Mechanism: GnRH-a treatment often leads to low estrogen levels, resulting in peri-menopausal symptoms and osteoporosis. Add-back therapy relieves clinical symptoms by supplementing low-dose estrogen. The idea of “combined regulation” is to improve symptoms by adding plant preparations or proprietary Chinese medicines. Studies have shown that they may play a role by regulating serotonin activity. Findings in Brief: For patients treated with GnRH-a for less than 3 months, the combined-regulation regimen can be considered, whereas for patients who have had more than 3 courses of GnRH-a, add-back therapy with sex hormones must be used because the patients will have begun to have obvious bone-mass loss and even bone pain; this bone-mass loss is often irreversible. Conclusions: In the early treatment of endometriosis with GnRH-a, non-hormone combined-regulation therapy is a relatively safe and feasible choice, but hormone add-back therapy should be selected for patients who have had more than 3 courses of GnRH-a. |
| format | Article |
| id | doaj-art-9bda9efe1ae042c39793d7c785ff1ea2 |
| institution | Kabale University |
| issn | 0390-6663 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj-art-9bda9efe1ae042c39793d7c785ff1ea22025-08-20T03:37:31ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632023-10-01501022410.31083/j.ceog5010224S0390-6663(23)02149-8Add-Back and Combined Regulation in GnRH-a Treatment of EndometriosisHuimin Tang0Qiucheng Jia1Zhiyong Dong2Yao Chen3Wulin Shan4Yihan Wu5Miao Miao6Tingwei Xing7Weiwei Wei8Bin Tang9Hong Zheng10Ruxia Shi11Bairong Xia12Jiming Chen13Department of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Obstetrics and Gynecology, Second Affiliated Hospital of Chongqing Medical University, 400010 Chongqing, ChinaDepartment of Gynecology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230031 Hefei, Anhui, ChinaDepartment of Gynecology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230031 Hefei, Anhui, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaDepartment of Gynecology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230031 Hefei, Anhui, ChinaDepartment of Gynecology, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, 213000 Changzhou, Jiangsu, ChinaObjective: The purpose of this review is to summarize drug selection for peri-menopausal symptoms caused by gonadotropin releasing-hormone agonist (GnRH-a) in the treatment of endometriosis. Mechanism: GnRH-a treatment often leads to low estrogen levels, resulting in peri-menopausal symptoms and osteoporosis. Add-back therapy relieves clinical symptoms by supplementing low-dose estrogen. The idea of “combined regulation” is to improve symptoms by adding plant preparations or proprietary Chinese medicines. Studies have shown that they may play a role by regulating serotonin activity. Findings in Brief: For patients treated with GnRH-a for less than 3 months, the combined-regulation regimen can be considered, whereas for patients who have had more than 3 courses of GnRH-a, add-back therapy with sex hormones must be used because the patients will have begun to have obvious bone-mass loss and even bone pain; this bone-mass loss is often irreversible. Conclusions: In the early treatment of endometriosis with GnRH-a, non-hormone combined-regulation therapy is a relatively safe and feasible choice, but hormone add-back therapy should be selected for patients who have had more than 3 courses of GnRH-a.https://www.imrpress.com/journal/CEOG/50/10/10.31083/j.ceog5010224add-back therapycombined regulationendometriosisgnrh-asex hormone |
| spellingShingle | Huimin Tang Qiucheng Jia Zhiyong Dong Yao Chen Wulin Shan Yihan Wu Miao Miao Tingwei Xing Weiwei Wei Bin Tang Hong Zheng Ruxia Shi Bairong Xia Jiming Chen Add-Back and Combined Regulation in GnRH-a Treatment of Endometriosis Clinical and Experimental Obstetrics & Gynecology add-back therapy combined regulation endometriosis gnrh-a sex hormone |
| title | Add-Back and Combined Regulation in GnRH-a Treatment of Endometriosis |
| title_full | Add-Back and Combined Regulation in GnRH-a Treatment of Endometriosis |
| title_fullStr | Add-Back and Combined Regulation in GnRH-a Treatment of Endometriosis |
| title_full_unstemmed | Add-Back and Combined Regulation in GnRH-a Treatment of Endometriosis |
| title_short | Add-Back and Combined Regulation in GnRH-a Treatment of Endometriosis |
| title_sort | add back and combined regulation in gnrh a treatment of endometriosis |
| topic | add-back therapy combined regulation endometriosis gnrh-a sex hormone |
| url | https://www.imrpress.com/journal/CEOG/50/10/10.31083/j.ceog5010224 |
| work_keys_str_mv | AT huimintang addbackandcombinedregulationingnrhatreatmentofendometriosis AT qiuchengjia addbackandcombinedregulationingnrhatreatmentofendometriosis AT zhiyongdong addbackandcombinedregulationingnrhatreatmentofendometriosis AT yaochen addbackandcombinedregulationingnrhatreatmentofendometriosis AT wulinshan addbackandcombinedregulationingnrhatreatmentofendometriosis AT yihanwu addbackandcombinedregulationingnrhatreatmentofendometriosis AT miaomiao addbackandcombinedregulationingnrhatreatmentofendometriosis AT tingweixing addbackandcombinedregulationingnrhatreatmentofendometriosis AT weiweiwei addbackandcombinedregulationingnrhatreatmentofendometriosis AT bintang addbackandcombinedregulationingnrhatreatmentofendometriosis AT hongzheng addbackandcombinedregulationingnrhatreatmentofendometriosis AT ruxiashi addbackandcombinedregulationingnrhatreatmentofendometriosis AT bairongxia addbackandcombinedregulationingnrhatreatmentofendometriosis AT jimingchen addbackandcombinedregulationingnrhatreatmentofendometriosis |